<DOC>
	<DOCNO>NCT00003828</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness vinorelbine treat patient stage IV melanoma previously treat .</brief_summary>
	<brief_title>S9804 : Vinorelbine Treating Patients With Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate response rate ( complete partial ) patient disseminate stage IV melanoma treat vinorelbine . II . Assess qualitative quantitative toxic effect vinorelbine patient . OUTLINE : Patients receive vinorelbine IV 6 10 minute weekly . Treatment continue absence disease progression , unacceptable toxicity , complete response therapy . Patients follow every 3 month 2 year every 6 month thereafter . PROJECTED ACCRUAL : A total 20-40 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm , pathologically verify , disseminate stage IV melanoma surgically incurable Any T , N , M1a M1b Must receive least one prior chemotherapy , biologic/immunotherapy , combination regimen metastatic disease At least 4 week since prior systemic therapy Bidimensionally measurable disease physical exam , CT scan , radionuclide scan , plain xray outside previously irradiate area No brain metastasis MRI CT scan ( except completely resect brain tumor undergone whole brain radiotherapy ) PATIENT CHARACTERISTICS : Age : Not specify Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : HIV negative Not pregnant nurse Fertile patient must use effective contraception No prior malignancy within past 5 year , except : Adequately treat basal cell squamous cell skin cancer Adequately treat stage I II cancer Carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 4 week since prior adjuvant biologic immunotherapy Chemotherapy : See Disease Characteristics No prior adjuvant chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy Surgery : At least 4 week since prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>